Almirall appoints Dr. Karl Ziegelbauer as Chief Scientific Officer 11 June 2021
  • Dr. Ziegelbauer has three decades of leadership experience in drug discovery and joins Almirall from Bayer Pharmaceuticals, where he most recently served as Senior Vice President and Head of Open Innovation & Digital Technologies
  • Dr. Ziegelbauer's appointment will be effective July 7, 2021, and he will be reporting directly to Almirall's CEO, Gianfranco Nazzi. He will also be a member of the company's Management Board

BARCELONA, Spain. June 11, 2021 - Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced today the appointment of Dr. Karl Ziegelbauer as Chief Scientific Officer (CSO), effective July 7, 2021.

Dr. Ziegelbauer joins Almirall from Bayer Pharmaceuticals, where he most recently served as Senior Vice President and Head of Open Innovation & Digital Technologies. Almirall's new CSO is a recognized industry leader and he brings with him three decades of leadership experience in drug discovery in international markets such as Germany, Japan, and the United States. He has developed most of his career at Bayer Pharmaceuticals and he has been assuming positions of increasing responsibility, holding Senior Vice President roles in various medical research fields. His experience encompasses different specialties such as oncology, cardiovascular diseases, anti-infectives, and immunology/inflammation.

In his new role at Almirall, Dr. Ziegelbauer will report directly to Gianfranco Nazzi, Almirall's Chief Executive Officer (CEO), and he will also be a member of the company's Management Board. He will be responsible for building strategic partnerships and developing and expanding Almirall's R&D pipeline in Medical Dermatology.

'At Almirall, we are committed to developing breakthrough products in the field of Medical Dermatology to address patient's unmet needs. We are convinced that with the appointment of Dr. Karl Ziegelbauer as our new CSO we will reinforce our pipeline, making a positive difference to patients' health', states Gianfranco Nazzi, Almirall's Chief Executive Officer.

Dr. Ziegelbauer is trained in biochemistry and molecular biology and holds a PhD in Biochemistry from the University of Tübingen (Germany). He has acquired extensive experience in leading large, global R&D organizations in strategy and portfolio management, as well as in building strategic partnerships with leading academic research institutions resulting in significant pipeline progression impact. He has co-authored more than 50 scientific publications covering basic research as well as drug discovery topics.

'I am thrilled to join such a dedicated, dynamic, and patient-focused team and be part of the journey to consolidate Almirall as a leader in Medical Dermatology', adds Dr. Karl Ziegelbauer.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: 'Transform the patients' world by helping them realize their hopes and dreams for a healthy life'. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit almirall.com

Attachments

  • Original document
  • Permalink

Disclaimer

Almirall SA published this content on 11 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 June 2021 09:23:01 UTC.